Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eisai Farmacêutica S.A. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to acquire additional information about the appropriate level of dosing of Zonisamide when it is prescribed for patients with partial onset epileptic crisis who are already being treated with two other antiepileptic drugs.
Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial onset epileptic crisis defined according to the International League Against Epilepsy (ILAE) criteria, with a minimum of two seizures within the 4 previous weeks, a stable treatment with two antiepileptic drugs for at least 12 weeks, and capable and willing to give their informed consent, will be included in the study.
To these patients, physicians will prescribe zonisamide in the following manner: Titration period of 12 weeks, at the end of which all patients must be taking 300 mg. Maintenance doses period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg. Six weeks later within this period, a decision will be made to raise the 400 mg doses up to 500 mg if considered necessary and tolerable.
Drugs will be prescribed by the physician and purchased by the patient.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Zonisamide | Drug | 300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of seizures. | Evaluations will be done at the beginning of the study (enrollment visit) and then one more time when 24 weeks had passed. |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life, tolerability. | Quality of Life evaluations will be done at the beginning of the study (enrollment visit) and then one more time when 24 weeks have passed. Tolerability will be assessed at the beginning of the study (enrollment visit) and at 12, 18, and 24 weeks. |
Not provided
Inclusion Criteria:
Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial onset epileptic seizures defined according to the International League Against Epilepsy (ILAE) criteria, with a minimum of two crises within the 4 previous weeks, a stable treatment with two antiepileptic drugs for at least 12 weeks and capable and willing to give their informed consent, will be included.
Exclusion Criteria:
Those who do not fulfill the Inclusion requirements.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jesus De Rosendo | EISAI Farmaceutica S.A. Head of Medical Department | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Complejo Hospitalario Universitario 'Juan Canalejo' | A Coruña | Galicia | 15006 | Spain | ||
| C.H. A. Marcide Profesor Novoa Santos |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Ferrol |
| Galicia |
| 15405 |
| Spain |
| Centro Sanitario Complexo Hospitalario "XERAL-CALDE" | Lugo | Galicia | 27004 | Spain |
| Hospital Comarcal de Monforte | Lugo | Galicia | 27400 | Spain |
| Centro Sanitario Hospital Da Costa de Burela | Lugo | Galicia | 27880 | Spain |
| Complejo Hospitalario de Ourense | Ourense | Galicia | 32005 | Spain |
| Complejo Hospitalario de Pontevedra | Pontevedra | Galicia | 36071 | Spain |
| Complejo Hospitalario Universitario Santiago de Compostela | Santiago de Compostela | Galicia | 15706 | Spain |
| Complejo Hospitalario Universitario de Vigo (CHUVI), Hospital Meixoeiro | Vigo | Galicia | 36204 | Spain |
| Hospital Povisa | Vigo | Galicia | 36211 | Spain |
| Complejo Hospitalario Universitario de Vigo (CHUVI), Hospital Xeral-Cies | Vigo | Galicia | 63204 | Spain |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078305 | Zonisamide |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D007555 | Isoxazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided